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Abstract 
The DNA fragments of omph and ompa were amplified by PCR from avian Pasteurella multocida. These fragments 
were inserted into pCDNA3.1(+) vector to construct DNA vaccines as follows: pCDNA-OMPH (pOMPH), pCDNA-
OMPA (pOMPA) and pCDNA-OMPH/OMPA (pOMPHA). The three plasmids were transfected into SP2 /0 cell in 
vitro. Expression of target genes were analyzed by indirect immunofluorescence. Four-weeks-old chickens were 
vaccinated with these DNA vaccines. The chickens injected with attenuated vaccine were positive control and the 
chickens injected with pCDNA3.1(+) were negative control. The serum antibodies were tested. Immunized chickens 
were challenged with virulent of avian Pasteurella multocida, the protection rate were counted. Results of ELISA 
showed the levels of antibodies in fusion DNA group were equivalent to group of attenuated vaccine, and 
significantly higher than the two single DNA groups (P<0.05). All the DNA vaccines could provide partial protection 
for chickens after the challenge. The protection rate of fusion DNA vaccine was higher than the attenuated vaccine, 
and the latter higher than the two single DNA vaccines. The results indicated DNA vaccines especially fusion DNA 
vaccines provide 
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1. Introduction 
Fowl cholera, caused by avian Pasteurella muhocida, is a contagious disease of poultry and fowl and 
is widely distributed in many countries. It seriously endanger the stable development of poultry industry. 
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The mjor control measures against this disease is drug treatment, particularly antibiotics, e.g. 
streptomycin sulfate, olaquindox etc. However, the disease is easy to relapse after drug withdrawal, the 
pathogen susceptible to drug resistance after long-term medication, and also may produce significant 
toxic effects to avian. Laying rate may be significant decrease in layers and drug residue in broilers. 
Therefore, it’s necessary to immunoprophylaxis with available vaccines for fundamentally control the 
prevalence of fowl cholera. 
Currently, the vaccines for prevention of fowl cholera include attenuated vaccine and Inactivated 
vaccine. The former was the most widely studied in the field of poultry attenuated vaccine research in 
china and achieved the development of peak in 1980s [1]. Nevertheless, the antigenic structure of avian 
Pasteurella muhocida is complicated, and prones to mutation. The protective effect achieved through 
commercial live vaccine is not ideal. The attenuated vaccine has some shortcomings, for instance, short-
term immunoprote--ction, poor protective effect and the possibility of excretion virion. Residual virulence 
may lead to degression of laying rate, and the disease may be outbreak after incorrect use [2]. The 
immunological effect of inactivated vaccine not as good as live vaccine, therefore, the inactivated vaccine 
rarely applied. 
DNA vaccine, which has the advantages of convenient preparation, low cost, easy to preserve, is 
currently the subject of intense investigation in the field of vaccine research [3]. DNA vaccines can 
prodive prolonged antigen expression, leading to boost of immune response and induce memory response 
against infection. So, DNA vaccines are known as the third revolution in the history of vaccine 
development. A variety of DNA vaccines against infectious diseases have been studied, such as AIDS, 
tuberculosis and so on [4,5]. 
In this study, we used the protective antigen genes omph and ompa of avian Pasteurella muhocida as 
the basis for construction of the monovalent and fusion DNA vaccines. Then chickens were vaccinated 
with these DNA vaccines, and the levels of antibodies and efficacy of protection were tested. The aim of 
this study was laying a foundation for further research and development of vaccines against Pasteurella 
muhocida infection.  
2. Materials and Methods 
2.1 Bacterial strains, vaccine and cells 
Pasteurella muhocida-CVCC474 strain was purchased from Chinese Institute of Veterinary Drug 
Control (IVDC). attenuated live vaccine was purchased from Qilu Animal Health Products Co., Ltd. 
competent cell DH5Į, mouse myeloma cell SP2/0 were conserve in the laboratory of He Nan university 
of science and technology in china. 
2.2 PCR amplification 
  Primes were designed according to the nucleotide sequences of the omph and ompa genes of 
Pasteurella muhocida strain Pm-17 and 95010872 respectively. Table. 1. lists the primer sequences. 
The target gene fragments were amplified using the genomic DNA as a template. The omph gene was 
amplified using primer pairs a˂b and a˂c, resulting in fragment A (containing the initiation and 
termination codons) and fragment B (containing the initiation). The ompa gene was amplified using 
primer pairs d˂e and f˂g, resulting in fragment C (containing the initiation and termination codons) and 
fragment D (containing the termination codons). 
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Table 1.  Primers sequences of omph and ompa gene 
Names                            Oligonucleotides primer sequences                              
omph (Kpn I)       5ƍ- TGAGGTACC|ATG|AAAAAGACAATCGTAG-3ƍ a 
omph EcoRI)      5ƍ- TAGGAATTCTTAGAAGTGTACGCGTAAAC -3ƍ b 
omph (BamHI)    5ƍ- TAATGGATCCGAAGTGTACGCGTAAAC -3ƍ c  
ompa  (Kpn I)     5ƍ-GCGGTACC|ATG|AAAAAAACAGCAATTGC-3ƍ d    
ompa (BamHI)    5ƍ-GCGGGATCCTTATTTGTTACCTTTAACAGCG-3ƍ e 
ompa (BamHI)    5ƍ-CGGGATCCAAAAAAACAGCAATTGC-3ƍ f 
ompa EcoRI)    5ƍ- CGCGCGAATTCTTATTTGTTACCTTTAACAGCG-3ƍ g 
Note: a, d: The KpnI recognition sequence is underlined and initiator is concluded;  b, g: The EcoRI recognition sequence is 
underlined and termination codon is concluded; c, e, f: The BamHI recognition sequence is underlined and the termination codon is 
concluded in e 
2.3 Construction of recombinant plasmids 
The purified gene fragments A and C were digested with KpnI/EcoRI and KpnI/BamHI, respectively. 
Then they were ligated into pcDNA3.1(+). Competent Escherichia coli DH5¢was transformed with the 
two recombinant plasmids. The plasmids were extracted and identified with restriction enzymes. The 
positive plasmids were named pcDNA3.1(+)-omph (pcH) and pcDNA3.1(+)-ompa (pcA), respectively. 
Fragment B was cloned into the KpnI/BamHI site of pcDNA3.1(+), followed by the insertion of fragment 
D into BamHI /EcoRI, resulting in the recombinant pasmid pcDNA3.1(+)-omph-ompa (pcHA). The 
plasmids were prepared on a large scale using the alkaline lysis method, and the plasmid preparations 
were adjusted to 1ȝg/ȝl using phosphate-buffered saline (PBS: 0.01M, pH 7.2) for futher experiments. 
2.4 Preparation of anti- serum
Rabbit anti- avian Pasteurella muhocida Omps serum was prepared as follows: Omps, extracted by 
supersonic split, was misced et fiat vaccine with vash oil and immunized rabbits. The rabbits were 
injected with 2mg of the above vaccine by subcutaneously, three times at 2-week intervals. The blood 
samples were drawn from the rabbits, serum was obtained and stored in -20ć refrigerDtor. 
2.5 Expression of recombinant plasmids in vitro 
One day before transfection, mouse myeloma SP2/0 cells at logarithmic growth phase were seeded 
into 24-well plates and grown at 37ÛC, 5%CO2 until 80% confluency. They were then transfected with 
0.8μg of pcH, pcA, pcHA and pcDNA3.1(+) using 2μl of Lipofectamine 2000  followed by indirect 
immunofluorescent testing after 72h [6]. Briefly, the cells were fixed with methanol/acetone for 20 min at 
room temperature, followed by addition of 200ȝl rabbit anti-Omps polyclonal antibody (1:40 dilution), 
and incubated in a moist chamber for 1 h at 37 ÛC. Next, 200 μl fluorescein isothiocyanate (FITC)-
labelled goat anti-rabbit IgG (1:100 dilution) containing 1% Evans blue was added; the samples were 
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incubated in a moist chamber for 1 h at 37 ÛC, and were then observed in a drop of basic glycerine under 
an inverted microscope to visualize blue-green fluorescence in SP2/0 cells. 
2.6 Immunization of chickens
Nonimmune chickens (n = 75), 1 day old, were purchased from the laboratory animal facility of henan 
province in China. DNA vaccination were carried out when the chickens were bred to 4 weeks of age. 
The animals were randomly assigned to immunization groups containing 15 chickens each. The chickens 
were immunized with 200μg of the DNA vaccines by intramuscular injection for each DNA 
immunization group. Chickens in the negative control groups were given empty vector pcDNA3.1. The 
animals in each of the above groups were immunized three times at 2-week intervals. In the positive 
control group, chickens were inoculated with 0.5ml attenuated live vaccine of avian Pasteurella 
muhocida at the time of initial vaccination. 
2.7 Serum antibody levels 
After immunization, blood samples were drawn from the chickens and serum specimens were isolated. 
The serum antibody titers were determined using indirect enzyme-linked immunosorbent assay (ELISA) 
[7]. Briefly, ELISA microtiter plates were coated with 109 cfuˋmL of avian Pasteurella muhocida 
suspension, followed by blocking nonspecific binding using 100 μl of 5% bovine serum albumin for 2 h. 
This was followed by the addition of 50 ȝl of serum (1:100 dilution), and the samples were incubated in a 
moist chamber at 37 ÛC for 1.5 h. The plates were washed three times with PBST and rabbit anti-chicken 
IgG- Horseradish peroxidase (HRP) was added and incubated at 37 ÛC for 1.5 h. Plates were washed three 
times with PBST, then 50μl Ortho-phenylene diamine (OPD, Sigma) was added and incubated for 10 min. 
Enzyme activity was stopped by adding an equal volume of 2M H2SO4, and the absorption was measured 
at 492 nm. Antibody titers were determined for up to 6 weeks before challenge. 
2.8 Challenge 
Every chicken was challenged 2 weeks after 3rd DNA immunization with the virulent strain CVCC474 
(5LD50/one chicken) by intramuscular. The chickens were reared for two weeks, the survival number and 
protection rate were counted. 
2.9 Statistical analysis 
The data from the experiments were expressed as meaQfstandard deviation (S.D.). Statistical analysis 
was conducted with SAS software. Analysis of variance was used to determine the significance of 
differences in means between the experimental groups. Difference with P˘0.05 were considered 
significant. 
3.  Results 
3.1 Expression of recombinant plasmids in vitro 
SP2/0 cells transfected with recombinant plasmids pcH, pcA and pcHA showed blue-green 
fluorescence under an inverting microscope, demonstrating that avian Pasteurella muhocida genes, omph, 
ompa and omph-ompa were transfected into SP2/0 cells and the cells expressed the target proteins. In 
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contrast, the SP2/0 cells transfected with pcDNA3.1(+) did not fluoresce (Fig. 1). 
 
Figure1. The results of omph, ompa and omph-ompa genes transfected into SP2/0 cells 
A, B, C, D: SP2/0 cells transfected by pcH, pcA, pcHA and pCDNA3.1(+). 
3.2 The antibodies induced by DNA vaccination 
Sera collected 1-6 weeks after the first vaccination were assayed for the presence of specific antibodies 
by indirect ELISA. As shown in Fig.2., strong humoral responses had been generated by the DNA 
vaccines and attenuated live vaccine. After immunization, the serum antibody levels in the attenuated live 
vaccine and pcHA-groups were significantly higher than those in pcH- and pcA-vaccinated groups 
(P<0.05) and in the negative control groups(P<0.01). There are no difference in the antibody levels 
among the attenuated live vaccine and pcHA-vaccinated groups (P>0.05), though the former was slightly 
higher than the latter two. In addition, the serum antibody levels in the two monogenic DNA vaccines 
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Figure 2. The dynamic changes of antibody level in serum from immune chickens 
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Following the first immunization, serum antibody levels were measured by indirected ELISA weekly until 6 weeks. Chickens were 
immunized with pcH vaccine (ƹ) ; pcA vaccine (Ƶ); pcHA vaccine (Ʒ); attenuated live vaccine h) DQG pcDNA3.1(+) vector (γ)
3.3 Challenge study 
Groups of chickens were challenged with live virulent avian Pasteurella muhocida CVCC474 strain 2 
weeks after last immunization. Survival number and protection rate were counted till 14days (Table. 2.). 
The mortality of chickens receiving pcDNA3.1(+) were almost 93.3% after challenge. The protection rate 
in the attenuated live vaccine and pcHA-vaccinated groups were higher in the pcH- and pcA-vaccinated 
groups (P<0.05). The survival of chickenls immunized with pcHA (73.3%) were lower than those in the 
chickens immunized with attenuated live vaccine (80%) 
Table 2. Protection of immunized chickens against lethal challenge with avian Pasteurella muhocida (*P<0.05, **P<0.01.) 
Groups                        Survival number/tota               Protection rate˄%˅ 
A. pcH                                    9/15                                         60* 
B. pcA                                    8/15                                        53.3* 
C. pcHA                                11/15                                      73.3** 
D. attenuated live vaccine     12/15                                      80** 
E. pCDNA3.1(+)                    1/15                                        6.7 
4. Discussion 
Outer membrane proteins of varied pathogenic bacteria have been recognised as immunodominant 
antigens [8, 9].The in-depth study about outer membrane proteins will help clarify their role in the 
pathogenesis and immune response of bacteria. Confer et al. vaccinated animals with Pasteurella 
muhocida and tested the level of serum antibodies by ELISA, and detected that 6 anti-Omps antibodies 
had relationships with the immune protection, and those antibodies could enhance the phagocytosis of 
macrophage and active complement. Their research indicated Omps of Pasteurella muhocida plays an 
important role in resistance to infection [10]. 
Out membrane proteins of Pasteurella muhocida comprises arch-protein and small protein, OmpH, 
OmpA, Oma87 and PlpB protein were the former. 
OmpH is the supr- microbore-protein of Pasteurella muhocida and the protective antigen. Luo et al. 
extracted OmpH protein, which had porin activity, and demonstrated that immunization of purified native 
OmpH was able to confer the protection of chickens from fowl cholera by challenge-exposure with 
parental strain X-73, the level of protection was equivalent to that achieved using whole cell after 
challenge. But the recombinant OmpH of strain X-73 induced little protection against challenge-exposure 
of parental strain[11]. Further research showed that OmpH proteins from different serotypes were highly 
homologous and had cross-protection [12]. 
OmpA, also called heat-modifiable protein, is a protective antigen of Pasteurella muhocida too. 
Experimental animal mortality was descend obviously after immunized with the monoclonal antibody 
against OmpA, which was prepared by Lu et al [13]. The same as OmpH, the research of Rimler showed 
OmpA proteins of Pasteurella muhocida had cross-protection among ifferent serotypes [14]. However, 
Some research results showed the protective effects provided by OmpA protein were not ideal, although it 
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could induce high level immune response [15]. So, the immunological effect created by OmpA protein of 
Pasteurella muhocida has not yet conclusive. 
Humoral immunoresponse is an important factor in resistance to avian Pasteurella muhocida infection. 
In this study, we detected the levels of antibodies induced by the DNA vaccines, and found that the 
abilities to stimulate humoral immunoresponse of the fusion DNA vaccines were correspond to that of 
attenuated live vaccine and surpass the two monovalent DNA vaccines. 
The Challenge experiment is one of the important index to evalue the protective efficacy of vaccines. In this 
study, chickens immunized with various vaccines were challenged with virulent avian Pasteurella muhocida. 
All the DNA vaccines could confer the protection on experiment animals. Among these DNA vaccines, the 
fusion DNA vaccine showed promise, and provides a valuable reference for the design of future DNA 
vaccines against fowl cholera. 
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